RxDoctor Payments Data

Natasha Carew

Psychiatric/Mental Health · Bridgewater, NJNPI 1184757817

Payments from drug & device makers

$1,424in general payments, 2019–2025

Across 54 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$529
  • GSK$526
  • Neurocrine Biosciences, Inc.$121
  • Lilly USA, LLC$90
  • Novo Nordisk$80
  • Merck$60
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$1,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,424 in reported general payments places this provider in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$4,244
Medicare patients
40
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol46$45,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$37,257
OzempicSemaglutide27$27,013
JanuviaSitagliptin Phosphate14$17,286
EliquisApixaban11$11,536
VascepaIcosapent Ethyl13$4,406
Albuterol Sulfate HfaAlbuterol Sulfate80$2,248
Humalog Kwikpen U-100Insulin Lispro14$2,228
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,631
Diclofenac Sodium21$1,278
Atorvastatin Calcium114$1,082
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide57$901
Rosuvastatin Calcium20$871
Lactulose14$848
Nifedipine ErNifedipine40$834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$529$45,59846 claims
GSKTrelegy Ellipta$526$37,25753 claims
Novo NordiskOzempic$80$27,01327 claims
MerckJanuvia$60$17,28614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →